Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 217

2.

CD44s is useful in the differentiation of benign and malignant papillary lesions of the breast.

Tse GM, Tan PH, Ma TK, Gilks CB, Poon CS, Law BK.

J Clin Pathol. 2005 Nov;58(11):1185-8.

3.

[Study of CD44v6 protein expression in intraductal papilloma and its malignant transformation of breast].

He JH, Liang XM, Hou JH, Huan YL, Wu QL, Xiao YB.

Ai Zheng. 2002 Jun;21(6):615-8. Chinese.

PMID:
12452061
4.

The role of immunohistochemistry for smooth-muscle actin, p63, CD10 and cytokeratin 14 in the differential diagnosis of papillary lesions of the breast.

Tse GM, Tan PH, Lui PC, Gilks CB, Poon CS, Ma TK, Law BK, Lam WW.

J Clin Pathol. 2007 Mar;60(3):315-20. Epub 2006 May 12.

5.

Cytokeratins in papillary lesions of the breast: is there a role in distinguishing intraductal papilloma from papillary ductal carcinoma in situ?

Tan PH, Aw MY, Yip G, Bay BH, Sii LH, Murugaya S, Tse GM.

Am J Surg Pathol. 2005 May;29(5):625-32.

PMID:
15832086
7.
8.

Use of a novel marker, calponin, for myoepithelial cells in fine-needle aspirates of papillary breast lesions.

Mosunjac MB, Lewis MM, Lawson D, Cohen C.

Diagn Cytopathol. 2000 Sep;23(3):151-5.

PMID:
10945900
9.

Intracystic papillary carcinomas of the breast: a reevaluation using a panel of myoepithelial cell markers.

Collins LC, Carlo VP, Hwang H, Barry TS, Gown AM, Schnitt SJ.

Am J Surg Pathol. 2006 Aug;30(8):1002-7.

PMID:
16861972
12.

Diagnostic evaluation of papillary lesions of the breast on core biopsy.

Pathmanathan N, Albertini AF, Provan PJ, Milliken JS, Salisbury EL, Bilous AM, Byth K, Balleine RL.

Mod Pathol. 2010 Jul;23(7):1021-8. doi: 10.1038/modpathol.2010.81. Epub 2010 May 14.

13.

The role of immunohistochemistry in the differential diagnosis of papillary lesions of the breast.

Tse GM, Tan PH, Moriya T.

J Clin Pathol. 2009 May;62(5):407-13. doi: 10.1136/jcp.2008.063016. Epub 2009 Jan 6. Review.

PMID:
19126567
14.

Immunohistochemical analysis of benign and malignant papillary lesions of the breast.

Papotti M, Eusebi V, Gugliotta P, Bussolati G.

Am J Surg Pathol. 1983 Jul;7(5):451-61.

PMID:
6351647
15.

Diagnostic utility of p75 neurotrophin receptor (p75NTR) as a marker of breast myoepithelial cells.

Popnikolov NK, Cavone SM, Schultz PM, Garcia FU.

Mod Pathol. 2005 Dec;18(12):1535-41.

16.

Immunohistochemical staining of papillary breast lesions.

Troxell ML, Masek M, Sibley RK.

Appl Immunohistochem Mol Morphol. 2007 Jun;15(2):145-53.

PMID:
17525625
17.

Clinical and cytologic features of papillary neoplasms of the breast.

Choi YD, Gong GY, Kim MJ, Lee JS, Nam JH, Juhng SW, Choi C.

Acta Cytol. 2006 Jan-Feb;50(1):35-40.

PMID:
16514838
18.

LOH at 16p13 is a novel chromosomal alteration detected in benign and malignant microdissected papillary neoplasms of the breast.

Lininger RA, Park WS, Man YG, Pham T, MacGrogan G, Zhuang Z, Tavassoli FA.

Hum Pathol. 1998 Oct;29(10):1113-8.

PMID:
9781650
19.

Papillary lesions of the breast: selected diagnostic and management issues.

Collins LC, Schnitt SJ.

Histopathology. 2008 Jan;52(1):20-9. doi: 10.1111/j.1365-2559.2007.02898.x. Review.

PMID:
18171414
20.

Usefulness of immunohistochemistry for differential diagnosis between benign and malignant breast lesions.

Moriya T, Kanomata N, Kozuka Y, Fukumoto M, Iwachido N, Hata S, Takahashi Y, Miura H, Ishida K, Watanabe M.

Breast Cancer. 2009;16(3):173-8. doi: 10.1007/s12282-009-0127-7. Epub 2009 May 28.

PMID:
19475479

Supplemental Content

Support Center